Melanoma Clinical Trial

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines (called binimetinib and cetuximab) in people with solid tumors.

This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer.

All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 1 or 2 times a day. Depending on the part of the study, participants may also receive another study medicine:

People with melanoma or other solid tumors may also receive binimetinib. Binimetinib comes as a tablet to take by mouth, 2 times a day.
People with colorectal cancer may also receive cetuximab. Cetuximab will be given weekly (or every two weeks) in the clinic as a shot given in the vein or port (intravenous, IV).

Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

View Eligibility Criteria

Eligibility Criteria

This study is seeking participants who meet the following eligibility criteria:

Inclusion Criteria:

Diagnosis of advanced/metastatic solid tumor including primary brain tumor.
Qualifying BRAF alteration (V600 or non-V600 Class II/Class III BRAF alteration), in tumor tissue and/or blood (ie circulating tumor deoxyribonucleic acid [DNA], or ctDNA).
Disease progressed during/following last prior treatment and no satisfactory alternative treatment options (Part 1 and Part 2).
Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies

Exclusion Criteria:

Brain metastasis larger than 4 cm
Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.
For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

174

Study ID:

NCT05355701

Recruitment Status:

Recruiting

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 27 Locations for this study

See Locations Near You

Highlands Oncology Group
Fayetteville Arkansas, 72703, United States
Highlands Oncology Group
Rogers Arkansas, 72758, United States
Highlands Oncology Group
Springdale Arkansas, 72762, United States
Clinical And Translational Research Center
Aurora Colorado, 80045, United States
UCHealth Sue Anschutz-Rodgers Eye Center
Aurora Colorado, 80045, United States
University of Colorado Anschutz Medical Campus
Aurora Colorado, 80045, United States
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
Aurora Colorado, 80045, United States
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora Colorado, 80045, United States
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora Colorado, 80045, United States
University of Miami Hospital and Clinics, Sylvester Cancer Center
Miami Florida, 33136, United States
Brigham and Women's Hospital
Boston Massachusetts, 02115, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
DFCI Chestnut Hill
Newton Massachusetts, 02459, United States
Brigitte Harris Cancer Pavilion
Detroit Michigan, 48202, United States
Henry Ford Hospital
Detroit Michigan, 48202, United States
Henry Ford Medical Center - Columbus
Novi Michigan, 48377, United States
MSK Monmouth
Middletown New Jersey, 07748, United States
MSK David H. Koch Center for Cancer Care
New York New York, 10021, United States
Memorial Sloan Kettering Cancer Center 53rd street
New York New York, 10022, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Cleveland Clinic Taussig Cancer Center Investigational Pharmacy
Cleveland Ohio, 44106, United States
Cleveland Clinic Taussing Cancer Center Investigational Pharmacy
Cleveland Ohio, 44106, United States
Cleveland Clinic
Cleveland Ohio, 44195, United States
Providence Cancer Institute Franz Clinic
Portland Oregon, 97213, United States
Providence Portland Medical Center
Portland Oregon, 97213, United States
Sarah Cannon Research Institute - Pharmacy
Nashville Tennessee, 37203, United States
Tennessee Oncology PLLC
Nashville Tennessee, 37203, United States
Tennessee Oncology, PLLC
Nashville Tennessee, 37203, United States
TriStar Bone Marrow Transplant
Nashville Tennessee, 37203, United States
TriStar Centennial Medical Center - Cell Processing Lab
Nashville Tennessee, 37203, United States
TriStar Centennial Medical center
Nashville Tennessee, 37203, United States
South Texas Accelerated Research Therapeutics (START)
San Antonio Texas, 78229, United States
Cross Cancer Institute
Edmonton Alberta, T6G 1, Canada
The Ottawa Hospital - General Campus
Ottawa Ontario, K1H 8, Canada
Princess Margaret Cancer Centre
Toronto Ontario, M5G 2, Canada
McGill University Health Centre
Montréal Quebec, H4A 3, Canada
Rabin Medical Center
Petah Tikva Hamerkaz, 49414, Israel
Sourasky Medical Center
Tel Aviv Tell Abīb, 64239, Israel
Hadassah Medical Center
Jerusalem Yerushalayim, 91120, Israel
Rambam Health Care Campus
Haifa Ḥeifā, 31096, Israel

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

174

Study ID:

NCT05355701

Recruitment Status:

Recruiting

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.